Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | CCNC | P24863 | 12/20 | 0.50 |
| ▸ | CDK8 | P49336 | 12/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17453074 | 0.87 | RIPK1 (0.48) | CCNCCDK8ADAM17RIPK1ROCK2 | |
| SCHEMBL17453078 | 0.85 | RIPK1 (0.47) | CCNCCDK8ADAM17RIPK1 | |
| SCHEMBL17453076 | 0.85 | CCNC (0.49) | CCNCCDK8ADAM17RIPK1ROCK2 | |
| SCHEMBL17453077 | 0.85 | RIPK1 (0.64) | HSD11B1ADAM17RIPK1 | |
| SCHEMBL14252999 | 0.85 | RIPK1 (0.64) | HSD11B1ADAM17RIPK1 | |
| SCHEMBL17454943 | 0.83 | HSD11B1 (0.54) | HSD11B1CCNCCDK8SMN1; SMN2RIPK1 | |
| SCHEMBL17142312 | 0.81 | HSD11B1 (0.59) | HSD11B1CCNCCDK8ADAM17SMN1; SMN2 | |
| SCHEMBL18406186 | 0.77 | ALDH1A1 (0.52) | HSD11B1CCNCCDK8SMN1; SMN2RIPK1 | |
| SCHEMBL14920930 | 0.77 | HSD11B1 (0.54) | HSD11B1CCNCCDK8SMN1; SMN2RIPK1 | |
| SCHEMBL11457784 | 0.77 | RIPK1 (0.39) | HSD11B1ADAM17RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | CDK8, CDK9, CDK18 | HSD11B1 2065/4885CCNC 31/4885CDK8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.